ACET: Rega marang dodolan Adicet Bio Inc.
Adicet Bio is developing affordable lymphoma therapy through T-cell programming, making the asset promising. The price-to-sales ratio on the chart confirms this trend, with the current level sitting around 10.80. Production relies on California-based centers and CDMO partners, while patent protection and FDA certification complexities create a significant barrier to entry for new market players.
Rincian analitis perusahaan Adicet Bio (ACET)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Koefisien Total Utang marang Modal Adicet Bio|ACET - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas adicetbio.com|ACET - Gunggung utang perusahaan|Utang-utang marang nilai buku Adicet|ACET - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Adicet Bio|Rasio jangkoan perantara adicetbio.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ACET - Bathi resik|Bathi sing dikarepake Adicet Bio|ACET - Pangali P/E|Kapitalisasi marang proyeksi bathi adicetbio.com|ACET - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Adicet|ACET - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Adicet Bio|ACET - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan adicetbio.com|ACET - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Adicet Bio
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:ACET - Adicet Bio Inc.
Adicet Bio occupies the niche of a cell therapy developer whose valuation currently depends on the prospects of clinical trials. Analyzing the fundamental P/S ratio allows an investor to see the relationship between market capitalization and annual revenue. An increase in this ratio amid stagnant sales indicates speculative overheating, whereas a decrease confirms undervaluation. For Adicet Bio, this metric remains formal until the company acquires real pricing power in the market.
Karo sapa Adicet Bio saingan
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX - Multiplikator P/S|IMVT: Multiplikator P/S|Rasio kapitalisasi marang pendapatan KNSA|GRFS (Grifols) - Multiplikator P/S|Adaptive Biotech (ADPT) - Koefisien rega marang pendapatan|Multiplikator P/S CLDX|Kapitalisasi marang pendapatan Aurinia Corp AUPH|Multiplikator P/S BCRX (BioCryst)|veratx.com (VERA) - Rega marang dodolan|DNTH: Kapitalisasi marang pendapatan|Pharvaris NV - Kapitalisasi marang volume dodolan|ABCL (AbCellera Biologics Inc) - Kapitalisasi marang pendapatan|Tourmaline - Rasio kapitalisasi pasar marang pendapatan|PGEN (Precigen, Inc.) - Multiplikator P/S|Rasio rega marang pendapatan PHAR|Multiplikator P/S NKTR|Koefisien rega marang pendapatan Upstream Bio, Inc.|Rasio rega marang pendapatan Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Rega marang dodolan|Gossamer Bio, Inc. - Multiplikator P/S|KALV - Multiplikator P/S|SEPN: Multiplikator P/S|Kapitalisasi marang pendapatan Pieris Pharma|SVRA (Savara Corp) - Multiplikator P/S|Rega marang dodolan Rigel Corp RIGL|Kapitalisasi marang pendapatan ANAB (AnaptysBio, Inc.)|Kapitalisasi marang volume dodolan ATXS|Rasio rega marang pendapatan enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Rasio rega marang dodolan|Aerovate - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACRS (Aclaris Therapeutics, Inc)|KYTX: Multiplikator P/S|tizianalifesciences.com (TLSA) - Multiplikator P/S|Rasio rega marang pendapatan Cabaletta Bio|VTYX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Theratechnologies Inc (THTX)|Kapitalisasi marang pendapatan Avalo Therapeutics Inc AVTX|Multiplikator P/S ELDN (Eledon Pharmaceuticals)|Multiplikator P/S agenusbio.com AGEN|CLYM: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ZURA (Zura Bio Ltd)|ATYR: Multiplikator P/S|ADAG - Koefisien rega marang pendapatan|Rasio rega marang pendapatan ImageneBio|Kapitalisasi marang pendapatan Shattuck Therapeutics (STTK)|Rasio rega marang pendapatan Equillium, Inc. (EQ)|Kapitalisasi marang pendapatan connectbiopharm.com CNTB|Immunic - Kapitalisasi marang pendapatan|Multiplikator P/S Atara Biotherapeutics, Inc. ATRA|IFRX - Rasio rega marang pendapatan|XFOR (x4pharma.com) - Rasio kapitalisasi marang pendapatan|CELU: Multiplikator P/S|Rega marang dodolan INmune Bio Inc (INMB)|BRNS (Barinthus Bio) - Multiplikator P/S|Multiplikator P/S Kezar Life Sciences Inc|Multiplikator P/S SABS|akaritx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd.)|Koefisien rega marang pendapatan Q32 Bio Inc (QTTB)|GeoVax Labs Inc - Multiplikator P/S|Edesa Biotech Corp (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|Rega marang dodolan Carisma Therapeutics Inc. (CARM)|Kapitalisasi marang pendapatan XTLB|BOLT (Bolt Bio) - Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan HCWB (HCW Biologics Inc.)|APVO (aptevotherapeutics.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S AIM (AIM ImmunoTech Inc.)|Aditxt Inc. - Rasio rega marang pendapatan|GRI Bio - Multiplikator P/S|Koefisien rega marang pendapatan XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Rasio rega marang pendapatan|Rega marang dodolan Revelation Biosciences Corp (REVB)|INDP (Indaptus Therapeutics) - Multiplikator P/S|Multiplikator P/S scinai.com|Multiplikator P/S CALI|Kapitalisasi marang pendapatan affimed.com AFMD|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Rega marang dodolan|IGMS: Kapitalisasi marang pendapatan|iteostherapeutics.com - Kapitalisasi marang volume dodolan|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rasio rega marang dodolan TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
